Boston Scientific Corporation (BSX) Stock Price & How to Invest

Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. It reports through two broad segments: Cardiovascular, which houses the electrophysiology business (led by the Farapulse pulsed field ablation system) and the Watchman left-atrial-appendage closure franchise, and MedSurg, which spans endoscopy, urology, and neuromodulation. The company sells into hospitals and physicians across roughly 130 countries and competes at the leading edge of catheter-based and device-based procedures that substitute for more invasive surgery.

Full-year 2025 revenue reached roughly $20.1 billion, with the Cardiovascular segment delivering about 21-22% organic growth on the strength of Farapulse (which launched in the United States in early 2024) and Watchman. Growth has cooled through 2026: first-quarter net sales of about $5.2 billion rose roughly 11.6% on a reported basis, and second-quarter revenue of about $5.4 billion rose about 7.5%. Adjusted EPS of $0.86 beat the $0.83 estimate in the second quarter, but in July management lowered its 2026 profit outlook (it had earlier guided adjusted EPS of about $3.34 to $3.41), citing weaker Watchman demand and US electrophysiology share losses to competitors. In September a cybersecurity incident disrupted manufacturing and shipments, and the company warned it was unlikely to meet its third-quarter and full-year sales and earnings forecasts. In October it also recalled 262,686 Imager II angiographic catheters worldwide over a tip-fracture risk. The investment picture now centers on whether the company can stabilize its newest franchises and recover from these setbacks, while defending share against much larger diversified rivals in a market where clinical trial data, physician training, and reimbursement determine winners.

The most immediate concern is a run of setbacks in 2026. Management lowered its profit outlook in July on weaker Watchman demand and US electrophysiology share losses, then in September said a cybersecurity incident had disrupted manufacturing and order shipments and that it was unlikely to meet its third-quarter and full-year sales and adjusted earnings forecasts. In October it recalled 262,686 Imager II angiographic catheters because the tip may fracture or detach during use, a reminder of the product-recall and safety-signal risk inherent to medical devices. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could further erode Boston Scientific's early PFA share and pressure pricing. Brokers including Baird, Truist and Mizuho trimmed price targets in mid-October 2026. Foreign exchange swings, hospital capital-spending cycles, reimbursement or regulatory changes, about $12.6 billion of debt, and integration risk from the company's acquisition strategy each add uncertainty.

29 analysts publish price targets on BSX, averaging $59.24 against a $44.39 price as of October 2026, or +33.5%. The published targets run from $44.00 to $94.00, a wide spread, and the ratings split 25 buy, 6 hold, 0 sell. Over the last six months there have been 0 raises and 10 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BSX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Boston Scientific Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Farapulse and the Pulsed Field Ablation Wave. The Farapulse pulsed field ablation (PFA) system remains the most important growth driver, helping the electrophysiology business post roughly 37% year-over-year growth in the fourth quarter of 2025. The most optimistic published target, $94.00, assumes this works close to its best case.

The case against. The most immediate concern is a run of setbacks in 2026. The most pessimistic target, $44.00, is roughly what BSX is worth if this bites instead.

Read the full bull and bear case on BSX, including what would have to change to break either one. Walnut is not an investment adviser.

No. Boston Scientific Corporation (BSX) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Boston Scientific Corporation's investor relations page or your broker.

• Revenue (TTM): ~$21 billion (+7.5% YoY in Q2 2026)
• Revenue (FY 2025): ~$20.1 billion
• Net income (TTM): ~$3.7 billion (profit margin ~17.5%)
• Adjusted EPS (Q2 2026): $0.86 vs $0.83 est.
• P/E Ratio (trailing / forward): ~18x / ~13x
• Market Cap: ~$64 billion

Boston Scientific's trailing P/E of roughly 18x and forward multiple near 13x are far below the sustained premium the stock carried during its high-growth phase. The compression followed a decline of about 55% over the past year, while the S&P 500 rose about 17%, driven by slowing growth, repeated outlook cuts, and the September cybersecurity disruption. Third-quarter results are due October 28, 2026, with consensus near $0.74 to $0.76 of adjusted EPS on revenue of about $5.1 billion, and the analyst mean target of about $59 sits well above the $44.06 share price, so the debate is whether the lower multiple reflects fair concern about decelerating growth or an over-correction.

Other names that sit close to BSX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get BSX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BSX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BSX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Boston Scientific today is a medical device franchise generating roughly $21 billion in trailing-twelve-month revenue, with Farapulse and Watchman as the core drivers. The central tension has shifted from whether premium growth can last to how far it has slowed: Watchman demand and US electrophysiology share have weakened, management cut its 2026 outlook in July and warned again in September, and the shares now trade near 13x forward earnings.

Whether BSX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BSX a buy or a sell?, and where the stock could go from here in the BSX stock forecast.

For income investors, whether BSX pays a dividend and how the payout looks is covered in does BSX pay a dividend? And to weigh BSX against a peer, read the full side-by-side comparisons: BSX vs MDT and BSX vs ABT.